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Abstract
Background: Severe acute respiratory syndrome (SARS) is a febrile respiratory illness. The
disease has been etiologically linked to a novel coronavirus that has been named the SARS-
associated coronavirus (SARS-CoV), whose genome was recently sequenced. Since it is a member
of the Coronaviridae, its spike protein (S2) is believed to play a central role in viral entry by
facilitating fusion between the viral and host cell membranes. The protein responsible for viral-
induced membrane fusion of HIV-1 (gp41) differs in length, and has no sequence homology with S2.
Results: Sequence analysis reveals that the two viral proteins share the sequence motifs that
construct their active conformation. These include (1) an N-terminal leucine/isoleucine zipper-like
sequence, and (2) a C-terminal heptad repeat located upstream of (3) an aromatic residue-rich
region juxtaposed to the (4) transmembrane segment.
Conclusions: This study points to a similar mode of action for the two viral proteins, suggesting
that anti-viral strategy that targets the viral-induced membrane fusion step can be adopted from
HIV-1 to SARS-CoV. Recently the FDA approved Enfuvirtide, a synthetic peptide corresponding to
the C-terminal heptad repeat of HIV-1 gp41, as an anti-AIDS agent. Enfuvirtide and C34, another
anti HIV-1 peptide, exert their inhibitory activity by binding to a leucine/isoleucine zipper-like
sequence in gp41, thus inhibiting a conformational change of gp41 required for its activation. We
suggest that peptides corresponding to the C-terminal heptad repeat of the S2 protein may serve
as inhibitors for SARS-CoV entry.
Background
Infection by many enveloped viruses requires fusion of
the viral and cellular membranes. A viral envelope protein
mediates this membrane fusion process. These proteins
are synthesized as precursors (ENV in Retroviridae, and E2
in Coronaviridae) that are later processed into a trans-
membrane subunit (gp41 in the retrovirus HIV-1, and S2
in the coronavirus SARS-CoV) that is responsible for viral-
induced membrane fusion, and a surface subunit that is
responsible for the interaction with the cellular receptor/s.
HIV-1 gp41, which is a well-characterized protein [1,2]
contains two heptad repeat (HR) regions, a leucine/iso-
leucine HR adjacent to its N-terminus (N-HR), and C-HR
proximal to the transmembrane domain (see Figure 1).
Heptad repeats are characterized by hydrophobic amino
acids in the "a" and "d" positions of the helix. In the N-HR
of gp41, all but one of the "a" positions are Leucines or
Isoleucines. This feature is less strict in the "d" positions
of N-HR, and in the "a" and "d" positions of the C-HR.
Peptides corresponding to these heptad repeat regions
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form the "trimer-of-hairpins" core structure of gp41 [3] as
confirmed by the solution of the crystal structures [1,2].
Two Cysteine residues and one Proline residue, located
between these two HRs, confine a hairpin conformation
(Figure 2a). A tryptophan-rich motif, located between the
C-HR and the transmembrane domain, was shown to play
a crucial role in gp41-mediated membrane fusion [4] (Fig-
ure 2a).
In order to exert their role in membrane fusion, viral spike
proteins act as oligomers and go through a significant
conformational change resulting in the "trimer-of-hair-
pin" conformation. The oligomerization and the change
in conformation of viral spike proteins involve interac-
tions between proteins segments. Peptides derived from a
segment of this protein might therefore interfere with one
of these processes, and inhibit viral infection. Indeed,
Wheel projection of the N-HR (a) and C-HR (b) of HIV-1 gp41 (gi|9629363) Figure 1
Wheel projection of the N-HR (a) and C-HR (b) of HIV-1 gp41 (gi|9629363). The amino acid sequence is displayed end-to-end 
down the axis of a schematic helix. The angle between every two consecutive amino acids is 102.9°. The helical wheel consists 
of seven corners, corresponding to the fit of seven amino acid residues into every two helical turns.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/20
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Similarity between the fusion proteins of HIV-1 and SARS-CoV Figure 2
Similarity between the fusion proteins of HIV-1 and SARS-CoV. The HIV-1 gp41 (a) and the equivalent S2 protein from the 
SARS-CoV (b) are shown. A Leucine/Isoleucine heptad repeat adjacent to the N-terminus of both proteins appears in red. The 
C-terminal heptad repeat is in green. Cysteine residues (purple) confining a loop structure are located between the two heptad 
repeats. An aromatic residues-rich motif is marked blue, and the transmembrane segment is in orange. A peptide correspond-
ing to the C-terminal heptad repeat, which acts as potent inhibitor of HIV-1 entry into the cell, appears in yellow.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/20
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peptides corresponding to the C-HR of gp41 are potent
inhibitors of HIV-1 entry into cells, one of them, Enfuvir-
tide (Fuzeon), was recently approved by the FDA as an
addition to the cocktail currently given to AIDS patients
[5], and C34, a peptide corresponding to the C-HR of the
gp41 core complex is promising in-vitro [1]. It is believed
that these peptides exert their anti-viral activity via a dom-
inant negative mechanism by interacting with the central
N-HR segment of gp41 [6]. This is a promising approach
also in developing anti-viral peptides against several para-
myxoviruses [7].
The genome of the SARS-CoV was recently sequenced
[8,9]. Since it is a member of the Coronaviridae [10], the
S2 protein is believed to play a central role in viral entry.
Although we found no sequence homology between the
SARS-CoV S2 and HIV-1 gp41, a comprehensive sequence
analysis reveals that all the above-mentioned elements of
gp41 are present also in S2.
In analogy to HIV-1 gp41, N-HR and an aromatic-rich
region in SARS-CoV S2 protein were identified by Galla-
her & Garry [11]. Whereas these discoveries have struc-
tural importance, peptides corresponding to the N-HR of
HIV-1 [12] and Sendai virus [13], and to the aromatic-rich
region of feline immunodeficiency virus [14] were found
to have only low anti-viral activity, compared to the
highly active C-HR corresponding peptides.
Herein, we report the identification of the sequence in
SARS-CoV S2 protein that is analogous to the C-HR of
HIV-1 gp41. This led us to the suggestion that the viral
entry mechanisms are analogous and therefore a thera-
peutic strategy that is being applied against the HIV-1 can
be adopted to fight SARS-CoV.
Results and discussion
Coronaviridae S2 proteins are believed to be functionally
equivalent to the transmembrane subunits of Retroviral
ENV. However, using well-known sequence comparison
algorithms [15,16], we found that there is no sequence
homology between the S2 protein of SARS-CoV and HIV-
1 gp41.
Markedly, LearnCoil-VMF [17], helical wheel analysis and
protein topology prediction [18] reveal that the SARS-CoV
S2 protein consists of the same elements that were charac-
terized in HIV-1 gp41 (Figure 2b): (I) N-HR, a Leucine/
Isoleucine heptad repeat appears on residues 913–1000 of
the SARS-CoV CUHK-W1 isolate (Figure 3a).; (II) C-HR, a
Leucine/Isoleucine heptad repeat appears on residues
1151–1185 (Figure 3b); (III) the loop between these two
HRs is longer than that of gp41, and is confined by four
Cysteine residues and nine Proline residues that might
conform a double loop structure; (IV) a transmembrane
region is predicted adjacent to the C-terminus of the pro-
tein [18]; (V) a Tryptophan/Tyrosine-rich motif is located
between the C-HR and the transmembrane domain (Fig-
ure 4). The results reveal similar structural motifs in HIV-
1 gp41 and SARS-CoV S2 proteins, suggesting an analo-
gous membrane fusion mechanism induced by the two
viruses.
The helical wheel diagram serves as an equivalent to the
Spartan scytale, the first military cryptographic device, con-
sisting of a cylinder with a strip of paper wound around it.
The recipient has a rod of the same diameter, on which he
wraps the paper to read the message. Herein, the prior
knowledge of the 3.5 periodicity learned from the HIV-1
gp41 structural studies, is used to decipher the structural
features of the SARS-CoV S2 protein.
In general, SARS-CoV S2 and HIV-1 gp41 share the hair-
pin structure. However, it is worth noting that the N-HR
of S2 is longer than that of gp41 and contains more
Leucines and Isoleucines. Furthermore, while the C-HR of
gp41 barely shows any heptad repeat signal, the C-HR of
S2 has a perfect Leucine/Isoleucine heptad repeat in its
"d" positions.
The antiviral activity of Enfuvirtide was reported as early
as 1993 [19], while it took few years until the fold of gp41
core complex was discovered [3] and its crystal structure
being solved [1,2]. Based on these structural studies, pep-
tides corresponding to the C-HR of gp41 core complex,
such as C34, were synthesized and found to efficiently
inhibit HIV-1 induced membrane fusion [1]. Interest-
ingly, Enfuvirtide, which is a shifted version of these C-
peptides, does not comprise the residues that were shown
to be essential for their inhibitory activity [20]. Indeed,
others and myself reported that in some cases C34 is more
potent in inhibiting HIV-1 gp41 induced membrane
fusion than Enfuvirtide [21,22]. Thus, the SARS-CoV
sequence corresponding to C34 has higher chances to
block SARS-CoV entry.
Conclusions
Based on the similarity in the mechanisms in which the
two viruses induce fusion between their membrane and
their host cell membrane, we propose adapting the suc-
cessful anti-fusion therapeutic approach used against
HIV-1 to the SARS-CoV case. Peptides derived from the C-
HR segment of SARS-CoV S2 protein (ISGINASVV-
NIQKEIDRLNEVAKNLNESLIDLQEL) might inhibit viral
induced membrane fusion, thereby blocking SARS-CoV
infection. As the SARS-CoV infects respiratory tissues, the
classical disadvantages of peptide therapeutics adminis-
tration may be overcome using intranasal delivery [23].BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/20
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Wheel projection of the N-HR (a) and C-HR (b) of SARS-CoV S2 protein (gi|30023954) Figure 3
Wheel projection of the N-HR (a) and C-HR (b) of SARS-CoV S2 protein (gi|30023954). The amino acid sequence is displayed 
end-to-end down the axis of a schematic helix. The angle between every two consecutive amino acids is 102.9°. The helical 
wheel consists of seven corners, corresponding to the fit of seven amino acid residues into every two helical turns.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/20
Page 6 of 7
(page number not for citation purposes)
Methods
Heptad repeat analysis
LearnCoil-VMF program [17] and helical wheel diagrams,
with 3.5 amino acid per residue, were used to detect
coiled-coil regions in the SARS-CoV S2 protein.
Transmembrane domain prediction
HMMTOP program [18] was used to predict the location
of transmembrane regions in the SARS-CoV S2 protein.
Protein sequences
SARS-CoV genomic sequence information (NC_004718)
was retrieved from GenBank at the National Center for
Biotechnology Information (NCBI). The SARS-CoV E2
precursor protein accession number is gi|30023954. This
precursor is believed to be post-translationally processed
to reveal S1 and S2, as confirmed in other Coronaviridae
viruses.
The HIV-1 gp160 precursor protein sequence used here is
gi|9629363. Gp41 starts at residue 512, after the basic
cleavage site.
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